Table 3.

Model predicted clinical outcomes over lifetime unless otherwise stated

Component	ACEI			Sacubitril/valsartan			Incremental
	UK	Denmark	Colombia	UK	Denmark	Colombia	UK	Denmark	Colombia
Life expectancy, years	8.36	7.34	7.95	9.27	8.07	8.78	0.91	0.73	0.83
Number of HF hospitalisations per patient	0.89	0.82	0.85	0.84	0.76	0.79	−0.05	−0.05	−0.05
Number of CV hospitalisations per patient	2.18	2.01	2.08	2.06	1.88	1.95	−0.13	−0.13	−0.13
All-cause hospitalisations	3.50	3.22	3.34	3.30	3.01	3.13	−0.20	−0.21	−0.21
All-cause mortality (%) at year 2	16%	20%	17%	14%	17%	15%	−0.02	−0.02	−0.02
All-cause mortality (%) at year 5	38%	44%	40%	33%	40%	36%	−0.05	−0.04	−0.04
All-cause mortality (%) at year 10	66%	72%	68%	60%	67%	63%	−0.05	−0.04	−0.05

ACEI, angiotensin-converting-enzyme inhibitor; CV, cardiovascular; HF, heart failure.